Guidelines for the hormone treatment of women in the menopausal transition and beyond

Climacteric

Volumn 7, Issue 1, 2004, Pages 8-11

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN;

BRAIN DISEASE; BREAST CARCINOMA; CANCER RISK; CAREGIVER; CLIMACTERIUM; CLINICAL TRIAL; CONFUSION; FEMALE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ORGANIZATION; HEART PROTECTION; HORMONAL THERAPY; HUMAN; MEDICAL INFORMATION; MEDICAL SOCIETY; MENOPAUSAL SYNDROME; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZATION; REVIEW; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; CLIMACTERIC; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN;

EID: 1642377226     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.1080/13697130310001651427     Document Type: Review

References (16)

1. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321-33
2. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-34
3. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. The Women's Health Initiative Randomized Trial. J Am Med Assoc 2003;289:3243-53
4. Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003;362:419-27
5. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary disease in postmenopausal women. J Am Med Assoc 1998;280:605-13
6. Herrington DM, Reboussin DR, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med 2000;343:522-9
7. Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003;348:1839-54
8. Naftolin F, Taylor HS, Karas R. Early initiation of hormone therapy and clinical cardioprotection: the Women's Health Initiative (WHI) could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertil Steril 2004: in press
9. Shapiro S. Effects of hormone replacement therapy on the risks of breast cancer and cardiovascular disease: the validity of the epidemiological evidence. In Schneider HPG, Naftolin F, eds. Climacteric Medicine - Where Do We Go? Proceedings of the 4th Workshop of the International Menopause Society. London: Parthenon Publishing, 2004:in press
10. Karas RH, Clarkson TB. Considerations in interpreting the cardiovascular effects of hormone replacement therapy observed in the WHI: timing is everything. Menopausal Med 2003;10:8-12
11. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-41
12. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone treatment and mortality. N Engl J Med 1997;336:1769-75
13. Joakimsen O, Bønaa KH, Stensland-Bugge E, Jacobsen BK. Population-based study of age at menopause and ultrasound assessed carotid atherosclerosis. J Clin Epidemiol 2000;53:525-30
14. Hu FB, Stampfer MJ, Manson JE, et al. Trends in the incidence of coronary heart disease and changes in diet and lifestyle in women. N Engl J Med 2000;343:530-7
15. Mack WJ, Hameed AB, Xiang M, et al. Does elevated body mass modify the influence of postmenopausal estrogen replacement on atherosclerosis progression: results from the estrogen in the prevention of atherosclerosis trial. Atherosclerosis 2003;168:91-8
16. Adams MR, Kaplan JR, Manuck SB, et al. Inhibition of coronary atherosclerosis by 17β-estradiol in ovariectomized monkeys: lack of an effect of added progesterone. Arteriosclerosis 1990;10:1051-7